Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A
The objective of this study is to assess the therapeutic safety and preliminary efficacy of a hematopoietic cell-based gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the FANCA gene in subjects with Fanconi anemia subtype A (FA-A).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: RP-L102
Eligibility
Inclusion Criteria:
- Fanconi anemia, as diagnosed by chromosomal fragility assay of cultured T-lymphocytes
in the presence of DEB or a similar DNA-crosslinking agent.
- Subjects of Fanconi Anemia complementation group A.
- Minimum age: 1 year and a minimum of 8 kg.
- Maximum age: 12 years.
- At least one of the following hematologic parameters below lower limits of normal:
- Hemoglobin
- Absolute neutrophils
- Platelets
- At least 30 CD34+ cells/μL are determined in one BM aspiration within 3 months prior
to initiation of CD34+ cell collection.
- If the number of C34+ cells/ μL in BM is in the range of 10-29, PB parameters should
meet two of the three following criteria:
- Hemoglobin: ≥11g/dL
- Neutrophils: ≥900 cells/μL
- Platelets: ≥60,000 cells/μL
- Provide informed consent in accordance with current legislation.
- Women of childbearing age must have a negative urine pregnancy test at the baseline
visit and accept the use of an effective contraception method during participation in
the trial.
Exclusion Criteria:
- Subjects with an available and medically eligible human leukocyte antigen
(HLA)-identical sibling donor.
- Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities
predictive of these conditions in BM aspirate analysis. This assessment should be made
by valid studies conducted within the 3 months before the subject commences the stem
cell mobilization/collection procedures of the clinical trial.
- Subjects with somatic mosaicism associated with stable or improved counts in all PB
cell lineages. (If T-lymphocyte chromosomal fragility analysis indicates potential
mosaicism, a medically significant decrease in at least one blood lineage over time
must be documented to enable eligibility).
- Lansky performance status ≤60%.
- Any concomitant disease or condition that, in the opinion of the Principal
Investigator, renders the subject unfit to participate in the study.
- Pre-existing sensory or motor impairment ≥grade 2 according to the NCI CTCAE v5.0
criteria.
- Pregnant or breastfeeding women.
- Hepatic dysfunction as defined by either:
- Bilirubin >3.0 × upper limit of normal (ULN) or
- Alanine aminotransferase (ALT) > 5.0 × ULN or
- Aspartate aminotransferase (AST) > 5.0 × ULN
- Renal dysfunction requiring either hemodialysis or peritoneal dialysis.
- Pulmonary dysfunction as defined by either:
- Need for supplemental oxygen during the prior 2 weeks in absence of acute
infection.
- Oxygen saturation by pulse oximetry <90%.
- Evidence of active metastatic or locoregionally advanced malignancy for which survival
is anticipated to be less than 3 years.
- Subject is receiving androgens (i.e. danazol, oxymethalone).
Ages Eligible for Study
1 Year - 12 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Elisabeth Merkel
(650) 497-6746
I'm interested
Psoriasis Clinical Trials
A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A
The objective of this study is to assess the therapeutic safety and preliminary efficacy of a hematopoietic cell-based gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the FANCA gene in subjects with Fanconi anemia subtype A (FA-A).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: RP-L102
Eligibility
Inclusion Criteria:
- Fanconi anemia, as diagnosed by chromosomal fragility assay of cultured T-lymphocytes
in the presence of DEB or a similar DNA-crosslinking agent.
- Subjects of Fanconi Anemia complementation group A.
- Minimum age: 1 year and a minimum of 8 kg.
- Maximum age: 12 years.
- At least one of the following hematologic parameters below lower limits of normal:
- Hemoglobin
- Absolute neutrophils
- Platelets
- At least 30 CD34+ cells/μL are determined in one BM aspiration within 3 months prior
to initiation of CD34+ cell collection.
- If the number of C34+ cells/ μL in BM is in the range of 10-29, PB parameters should
meet two of the three following criteria:
- Hemoglobin: ≥11g/dL
- Neutrophils: ≥900 cells/μL
- Platelets: ≥60,000 cells/μL
- Provide informed consent in accordance with current legislation.
- Women of childbearing age must have a negative urine pregnancy test at the baseline
visit and accept the use of an effective contraception method during participation in
the trial.
Exclusion Criteria:
- Subjects with an available and medically eligible human leukocyte antigen
(HLA)-identical sibling donor.
- Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities
predictive of these conditions in BM aspirate analysis. This assessment should be made
by valid studies conducted within the 3 months before the subject commences the stem
cell mobilization/collection procedures of the clinical trial.
- Subjects with somatic mosaicism associated with stable or improved counts in all PB
cell lineages. (If T-lymphocyte chromosomal fragility analysis indicates potential
mosaicism, a medically significant decrease in at least one blood lineage over time
must be documented to enable eligibility).
- Lansky performance status ≤60%.
- Any concomitant disease or condition that, in the opinion of the Principal
Investigator, renders the subject unfit to participate in the study.
- Pre-existing sensory or motor impairment ≥grade 2 according to the NCI CTCAE v5.0
criteria.
- Pregnant or breastfeeding women.
- Hepatic dysfunction as defined by either:
- Bilirubin >3.0 × upper limit of normal (ULN) or
- Alanine aminotransferase (ALT) > 5.0 × ULN or
- Aspartate aminotransferase (AST) > 5.0 × ULN
- Renal dysfunction requiring either hemodialysis or peritoneal dialysis.
- Pulmonary dysfunction as defined by either:
- Need for supplemental oxygen during the prior 2 weeks in absence of acute
infection.
- Oxygen saturation by pulse oximetry <90%.
- Evidence of active metastatic or locoregionally advanced malignancy for which survival
is anticipated to be less than 3 years.
- Subject is receiving androgens (i.e. danazol, oxymethalone).
Ages Eligible for Study
1 Year - 12 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Elisabeth Merkel
(650) 497-6746
I'm interested
Dermatology Clinical Trials
A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A
The objective of this study is to assess the therapeutic safety and preliminary efficacy of a hematopoietic cell-based gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the FANCA gene in subjects with Fanconi anemia subtype A (FA-A).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: RP-L102
Eligibility
Inclusion Criteria:
- Fanconi anemia, as diagnosed by chromosomal fragility assay of cultured T-lymphocytes
in the presence of DEB or a similar DNA-crosslinking agent.
- Subjects of Fanconi Anemia complementation group A.
- Minimum age: 1 year and a minimum of 8 kg.
- Maximum age: 12 years.
- At least one of the following hematologic parameters below lower limits of normal:
- Hemoglobin
- Absolute neutrophils
- Platelets
- At least 30 CD34+ cells/μL are determined in one BM aspiration within 3 months prior
to initiation of CD34+ cell collection.
- If the number of C34+ cells/ μL in BM is in the range of 10-29, PB parameters should
meet two of the three following criteria:
- Hemoglobin: ≥11g/dL
- Neutrophils: ≥900 cells/μL
- Platelets: ≥60,000 cells/μL
- Provide informed consent in accordance with current legislation.
- Women of childbearing age must have a negative urine pregnancy test at the baseline
visit and accept the use of an effective contraception method during participation in
the trial.
Exclusion Criteria:
- Subjects with an available and medically eligible human leukocyte antigen
(HLA)-identical sibling donor.
- Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities
predictive of these conditions in BM aspirate analysis. This assessment should be made
by valid studies conducted within the 3 months before the subject commences the stem
cell mobilization/collection procedures of the clinical trial.
- Subjects with somatic mosaicism associated with stable or improved counts in all PB
cell lineages. (If T-lymphocyte chromosomal fragility analysis indicates potential
mosaicism, a medically significant decrease in at least one blood lineage over time
must be documented to enable eligibility).
- Lansky performance status ≤60%.
- Any concomitant disease or condition that, in the opinion of the Principal
Investigator, renders the subject unfit to participate in the study.
- Pre-existing sensory or motor impairment ≥grade 2 according to the NCI CTCAE v5.0
criteria.
- Pregnant or breastfeeding women.
- Hepatic dysfunction as defined by either:
- Bilirubin >3.0 × upper limit of normal (ULN) or
- Alanine aminotransferase (ALT) > 5.0 × ULN or
- Aspartate aminotransferase (AST) > 5.0 × ULN
- Renal dysfunction requiring either hemodialysis or peritoneal dialysis.
- Pulmonary dysfunction as defined by either:
- Need for supplemental oxygen during the prior 2 weeks in absence of acute
infection.
- Oxygen saturation by pulse oximetry <90%.
- Evidence of active metastatic or locoregionally advanced malignancy for which survival
is anticipated to be less than 3 years.
- Subject is receiving androgens (i.e. danazol, oxymethalone).
Ages Eligible for Study
1 Year - 12 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Elisabeth Merkel
(650) 497-6746
I'm interested
Pediatric Dermatology Clinical Trials
A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A
The objective of this study is to assess the therapeutic safety and preliminary efficacy of a hematopoietic cell-based gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the FANCA gene in subjects with Fanconi anemia subtype A (FA-A).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: RP-L102
Eligibility
Inclusion Criteria:
- Fanconi anemia, as diagnosed by chromosomal fragility assay of cultured T-lymphocytes
in the presence of DEB or a similar DNA-crosslinking agent.
- Subjects of Fanconi Anemia complementation group A.
- Minimum age: 1 year and a minimum of 8 kg.
- Maximum age: 12 years.
- At least one of the following hematologic parameters below lower limits of normal:
- Hemoglobin
- Absolute neutrophils
- Platelets
- At least 30 CD34+ cells/μL are determined in one BM aspiration within 3 months prior
to initiation of CD34+ cell collection.
- If the number of C34+ cells/ μL in BM is in the range of 10-29, PB parameters should
meet two of the three following criteria:
- Hemoglobin: ≥11g/dL
- Neutrophils: ≥900 cells/μL
- Platelets: ≥60,000 cells/μL
- Provide informed consent in accordance with current legislation.
- Women of childbearing age must have a negative urine pregnancy test at the baseline
visit and accept the use of an effective contraception method during participation in
the trial.
Exclusion Criteria:
- Subjects with an available and medically eligible human leukocyte antigen
(HLA)-identical sibling donor.
- Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities
predictive of these conditions in BM aspirate analysis. This assessment should be made
by valid studies conducted within the 3 months before the subject commences the stem
cell mobilization/collection procedures of the clinical trial.
- Subjects with somatic mosaicism associated with stable or improved counts in all PB
cell lineages. (If T-lymphocyte chromosomal fragility analysis indicates potential
mosaicism, a medically significant decrease in at least one blood lineage over time
must be documented to enable eligibility).
- Lansky performance status ≤60%.
- Any concomitant disease or condition that, in the opinion of the Principal
Investigator, renders the subject unfit to participate in the study.
- Pre-existing sensory or motor impairment ≥grade 2 according to the NCI CTCAE v5.0
criteria.
- Pregnant or breastfeeding women.
- Hepatic dysfunction as defined by either:
- Bilirubin >3.0 × upper limit of normal (ULN) or
- Alanine aminotransferase (ALT) > 5.0 × ULN or
- Aspartate aminotransferase (AST) > 5.0 × ULN
- Renal dysfunction requiring either hemodialysis or peritoneal dialysis.
- Pulmonary dysfunction as defined by either:
- Need for supplemental oxygen during the prior 2 weeks in absence of acute
infection.
- Oxygen saturation by pulse oximetry <90%.
- Evidence of active metastatic or locoregionally advanced malignancy for which survival
is anticipated to be less than 3 years.
- Subject is receiving androgens (i.e. danazol, oxymethalone).
Ages Eligible for Study
1 Year - 12 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Elisabeth Merkel
(650) 497-6746
I'm interested
A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A
The objective of this study is to assess the therapeutic safety and preliminary efficacy of a hematopoietic cell-based gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the FANCA gene in subjects with Fanconi anemia subtype A (FA-A).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: RP-L102
Eligibility
Inclusion Criteria:
- Fanconi anemia, as diagnosed by chromosomal fragility assay of cultured T-lymphocytes
in the presence of DEB or a similar DNA-crosslinking agent.
- Subjects of Fanconi Anemia complementation group A.
- Minimum age: 1 year and a minimum of 8 kg.
- Maximum age: 12 years.
- At least one of the following hematologic parameters below lower limits of normal:
- Hemoglobin
- Absolute neutrophils
- Platelets
- At least 30 CD34+ cells/μL are determined in one BM aspiration within 3 months prior
to initiation of CD34+ cell collection.
- If the number of C34+ cells/ μL in BM is in the range of 10-29, PB parameters should
meet two of the three following criteria:
- Hemoglobin: ≥11g/dL
- Neutrophils: ≥900 cells/μL
- Platelets: ≥60,000 cells/μL
- Provide informed consent in accordance with current legislation.
- Women of childbearing age must have a negative urine pregnancy test at the baseline
visit and accept the use of an effective contraception method during participation in
the trial.
Exclusion Criteria:
- Subjects with an available and medically eligible human leukocyte antigen
(HLA)-identical sibling donor.
- Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities
predictive of these conditions in BM aspirate analysis. This assessment should be made
by valid studies conducted within the 3 months before the subject commences the stem
cell mobilization/collection procedures of the clinical trial.
- Subjects with somatic mosaicism associated with stable or improved counts in all PB
cell lineages. (If T-lymphocyte chromosomal fragility analysis indicates potential
mosaicism, a medically significant decrease in at least one blood lineage over time
must be documented to enable eligibility).
- Lansky performance status ≤60%.
- Any concomitant disease or condition that, in the opinion of the Principal
Investigator, renders the subject unfit to participate in the study.
- Pre-existing sensory or motor impairment ≥grade 2 according to the NCI CTCAE v5.0
criteria.
- Pregnant or breastfeeding women.
- Hepatic dysfunction as defined by either:
- Bilirubin >3.0 × upper limit of normal (ULN) or
- Alanine aminotransferase (ALT) > 5.0 × ULN or
- Aspartate aminotransferase (AST) > 5.0 × ULN
- Renal dysfunction requiring either hemodialysis or peritoneal dialysis.
- Pulmonary dysfunction as defined by either:
- Need for supplemental oxygen during the prior 2 weeks in absence of acute
infection.
- Oxygen saturation by pulse oximetry <90%.
- Evidence of active metastatic or locoregionally advanced malignancy for which survival
is anticipated to be less than 3 years.
- Subject is receiving androgens (i.e. danazol, oxymethalone).
Ages Eligible for Study
1 Year - 12 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Elisabeth Merkel
(650) 497-6746
I'm interested
A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A
The objective of this study is to assess the therapeutic safety and preliminary efficacy of a hematopoietic cell-based gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the FANCA gene in subjects with Fanconi anemia subtype A (FA-A).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: RP-L102
Eligibility
Inclusion Criteria:
- Fanconi anemia, as diagnosed by chromosomal fragility assay of cultured T-lymphocytes
in the presence of DEB or a similar DNA-crosslinking agent.
- Subjects of Fanconi Anemia complementation group A.
- Minimum age: 1 year and a minimum of 8 kg.
- Maximum age: 12 years.
- At least one of the following hematologic parameters below lower limits of normal:
- Hemoglobin
- Absolute neutrophils
- Platelets
- At least 30 CD34+ cells/μL are determined in one BM aspiration within 3 months prior
to initiation of CD34+ cell collection.
- If the number of C34+ cells/ μL in BM is in the range of 10-29, PB parameters should
meet two of the three following criteria:
- Hemoglobin: ≥11g/dL
- Neutrophils: ≥900 cells/μL
- Platelets: ≥60,000 cells/μL
- Provide informed consent in accordance with current legislation.
- Women of childbearing age must have a negative urine pregnancy test at the baseline
visit and accept the use of an effective contraception method during participation in
the trial.
Exclusion Criteria:
- Subjects with an available and medically eligible human leukocyte antigen
(HLA)-identical sibling donor.
- Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities
predictive of these conditions in BM aspirate analysis. This assessment should be made
by valid studies conducted within the 3 months before the subject commences the stem
cell mobilization/collection procedures of the clinical trial.
- Subjects with somatic mosaicism associated with stable or improved counts in all PB
cell lineages. (If T-lymphocyte chromosomal fragility analysis indicates potential
mosaicism, a medically significant decrease in at least one blood lineage over time
must be documented to enable eligibility).
- Lansky performance status ≤60%.
- Any concomitant disease or condition that, in the opinion of the Principal
Investigator, renders the subject unfit to participate in the study.
- Pre-existing sensory or motor impairment ≥grade 2 according to the NCI CTCAE v5.0
criteria.
- Pregnant or breastfeeding women.
- Hepatic dysfunction as defined by either:
- Bilirubin >3.0 × upper limit of normal (ULN) or
- Alanine aminotransferase (ALT) > 5.0 × ULN or
- Aspartate aminotransferase (AST) > 5.0 × ULN
- Renal dysfunction requiring either hemodialysis or peritoneal dialysis.
- Pulmonary dysfunction as defined by either:
- Need for supplemental oxygen during the prior 2 weeks in absence of acute
infection.
- Oxygen saturation by pulse oximetry <90%.
- Evidence of active metastatic or locoregionally advanced malignancy for which survival
is anticipated to be less than 3 years.
- Subject is receiving androgens (i.e. danazol, oxymethalone).
Ages Eligible for Study
1 Year - 12 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Elisabeth Merkel
(650) 497-6746
I'm interested